cultivateMD is a unique medical device venture capital fund.

We are unique because we leverage our many years of seasoned healthcare experience across all disciplines. This experience empowers us to come alongside exciting technology companies to positively impact their performance and results.

We focus on investing in technologies that improve outcomes and reduce costs from the healthcare system.

The healthcare and medical device space is a top area of focus, spending and high growth worldwide.  This, of course, creates a very healthy and positive environment for strategic investors.

medical device venture capital cultivate md medical investment

Our Healthcare Expertise Is What Sets Us Apart

We are a very focused medical device venture capital fund filled with 22 professionals–most of whom are technical engineers or scientists.

Beginning in 2014 our purpose was to raise additional capital to invest along with our own personal investment capital that we could deploy in the technologies we believe are most valuable with the intention that we could play a significant and beneficial role in increasing their value.

Since that time we have taken on a number of exciting opportunities including one that has already turned into a very successful transaction.

cultivate(MD) Capital Fund Advisors

Steve Bishop

Steve Bishop

Retired CEO, Procter and Gamble Health Care

  • 35+ yrs at Procter and Gamble, leading a $10 Billion business, sold in over 170 countries around the world
  • Extensive experience in market-leading consumer medical devices and over-the-counter drug products
  • Track record of significant growth, both through organic and M&A, including the multi-$billion acquisition of Merck KGaA Consumer Health Care
  • 1/3 of career in executive global management roles residing in both US and EU
  • Board experience includes Cintrifuse, a public/private partnership to create a tech-based startup ecosystem in the southwest Ohio region;  includes two Venture Funds
Paul Buckman

Paul Buckman

President of North American Operations at LivaNova

  • 30+ Years Experience in Medical Device Industry
  • Leadership Roles Across Healthcare Disciplines
  • President of Cardiology Division at Boston Scientific Corporation
  • CEO of Conventus Orthopaedics
  • CEO of Sentreheart
  • CEO & Chairman of Pathway Medical Technologies, Inc.
  • CEO of Devax, inc.
  • President of St. Jude Medical’s Cardiology Division
Nathan Estruth

Nathan Estruth

Vice-Chairman, KPS Global Board of Directors

  • Experienced Fortune 20 Global Executive & Officer
  • 27 Years at Procter & Gamble, VP,   Corp New Business & Innovation
  • CEO, iMFLUX Inc. (software, tooling, and injection molding)
  • Board Member Experience:
    • Songbird (medical device)
    • Agile Pursuits
    • Navigenics (genomics)
    • MDVIP (primary care)
    • KPS Global (vaccine, blood bank infrastructure/ops)
    • HealthPoint Services (Apollo Hospital Group, India)
Dr. Dan Blue

Dr. Daniel Blue, MD

Former President, World Clinics, Sanford Health

  • 30+ Years as Family Practice Physician at Sanford Health
  • Leadership Roles in Healthcare Industry
    • CMO of Sioux Valley Clinic
    • President of Sanford Clinic
    • President of Sanford World Clinic
Dr. Michael Alexiades

Dr. Michael Alexiades, MD

Practicing Orthopedic Specialist Hospital for Special Surgery, NYC

  • 30+ Years Experience Developing Hip & Knee Replacement Implants
  • Examiner for American Board of Orthopedic Surgery

Reducing The Risk Associated With Medical Device Venture Capital

A big part of what makes us unique is that we believe we can reduce the investment risk by engaging in the actual operations of the companies we invest in.

We have a very effective means to deploy capital in an attractive way that can reduce risk by fully engaging the team that we’ve put in place. At the same time, we needed to infuse more capital in some of the businesses we had already engaged in order to continue to drive our success.

The cultivate(MD) Medical Device Investment Strategy

With our unique background and expertise, we are able to engage medical device companies at an earlier stage with a greater amount of confidence. This allows us to make investments at early–when valuations are much more attractive.

This also typically provides us with larger ownership percentages in companies–which enables us to have a greater role in the governance and operations of the companies we invest in.

This allows us to effectively mitigate the risk of ongoing or follow-on investments.

Deal Access and Capital Deployment

One of the most prominent challenges investors or venture capital firms typically face is not just fundraising–it’s getting access to the right deals in which to deploy those funds.

With our vast experience in the medical device space, we have an extensive network that provides us access to vet opportunities that are the best fit for our unique model and investors.

Additionally, many large medical device companies are offloading more development opportunities. This creates a wealth of opportunities for our team and us. These large, multi-national medical device companies have such a need for innovation, they are actively searching for opportunities that are pre-FDA filing, pre-FDA clearance, pre-revenue.

cultivate md medical investment outlook

The material value can be derived from the innovation that takes place even before the asset is commercially ready or is de-risked. Frequently, those early stages are not very costly. There are many opportunities to create a lot of strategic value for not a lot of cash. From our many years in the medical device space and having the networks already established, we are able to quickly pursue and vet these opportunities.

Our deal access often comes at a very early stage, typically pre-Series A investments. Through experience, this is where we understand the strategy and can really leverage our multi-talented expertise.

cultivate(MD) Operations and Terms


cultivate MD operates as a very traditional medical device venture capital fund. As an investor, you can invest in a fund, and we then deploy those funds into the investments without the pass-through of Genesis.

Our focus is to execute the fundraising in a way that’s most advantageous to our investors.

The terms of the investment are simple and investor friendly. There is a minimum investment of $100,000 for one unit. That investment is broken down into four time-based draws over a longer period of time (2.5-3.5 year period).

We charge a 2.5% management fee on the total commitment of the fund, and we have a 20% carry on the amount distributed over the initial investment. Essentially, there’s no carry until all investors have received their initial capital back in their hands.

Learn More About Future cultivate(MD) Investment Opportunities

Please fill out the information below and someone from our team will personally reach out to you.